Flaxseed cotyledon fraction reduces tumour growth and sensitises tamoxifen treatment of human breast cancer xenograft (MCF-7) in athymic mice

British Journal of Nutrition

Volumn 105, Issue 3, 2011, Pages 339-347

  Chen, Jianmin ^a   Saggar, Jasdeep K ^a   Corey, Paul ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Cotyledon fractions; Flaxseed; Tamoxifen

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTRADIOL; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; MESSENGER RNA; OMEGA 3 FATTY ACID; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN PS2; SOMATOMEDIN C RECEPTOR; STEROID RECEPTOR COACTIVATOR 3; TAMOXIFEN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CANCER SIZE; CANCER TISSUE; CELL STRAIN MCF 7; CONTROLLED STUDY; COTYLEDON; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG IMPLANT; DRUG SENSITIZATION; ESTRADIOL BLOOD LEVEL; FACTORIAL DESIGN; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LINSEED; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; COTYLEDON; FEMALE; FLAX; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; PHYTOTHERAPY; SEEDS; TAMOXIFEN; TRANSPLANTATION, HETEROLOGOUS;

MUS;

EID: 79951599190     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114510003557     Document Type: Article

References (51)

1. Thompson LU (2003) Flaxseed, lignans, and cancer. In Flax-seed in Human Nutrition, 2nd ed., pp. 194-222 [LU Thompson and SC Cunnane, editors]. Champaign: AOCS Press.
2. Bougnoux P & Chajes V (2003) Alpha-linolenic acid and cancer. In Flaxseed in Human Nutrition, 2nd ed., pp. 232-244 [LU Thompson and SC Cunnane, editors]. Champaign: AOCS Press.
3. Cunnane SC (2003) Dietary sources and metabolism of a-linolenic acid. In Flaxseed in Human Nutrition, 2nd ed., pp. 63-91 [LU Thompson and SC Cunnane, editors]. Champaign: AOCS Press.
4. Thompson LU, Robb P, Serraino M, et al. (1991) Mammalian lignan production from various foods. Nutr Cancer 16, 43-52.
5. Thompson LU, Boucher BA, Liu Z, et al. (2006) Phytoestro-gen content of foods consumed in Canada, including isoflavones, lignans, and coumestan. Nutr Cancer 54, 184-201. (Pubitemid 44316301)
6. Adlercreutz H (2007) Lignans and human health. Crit Rev Clin Lab Sci 44, 483-525. (Pubitemid 47619399)
7. Serraino M & Thompson LU (1991) The effect of flaxseed supplementation on early risk markers for mammary car-cinogenesis. Cancer Lett 60, 135-142.
8. Serraino M & Thompson LU (1991) The effect of flaxseed supplementation on the initiation and promotional stages of mammary tumorigenesis. Nutr Cancer 17, 153-159.
9. Thompson LU, Rickard SE, Orcheson LJ, et al. (1996) Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogenesis 17, 1373-1376. (Pubitemid 26197671)
10. Thompson LU, Seidl MM, Rickard SE, et al. (1996) Antitumorigenic effect of a mammalian lignan precursor from flaxseed. Nutr Cancer 26, 159-165. (Pubitemid 26300195)
11. Chen J, Hui E, Ip T, et al. (2004) Dietary flaxseed enhances the inhibitory effect of tamoxifen on the growth of estrogen-dependent human breast cancer (MCF-7) in nude mice. Clin Cancer Res 10, 7703-7711. (Pubitemid 39557535)
12. Saarinen NM, Power KA, Chen J, et al. (2006) Flaxseed attenuates the tumor growth stimulating effect of soy protein in ovariectomized athymic mice with MCF-7 human breast cancer xenografts. Int J Cancer 119, 925-931. (Pubitemid 44051460)
13. Chen J, Power KA, Mann J, et al. (2007) Dietary flaxseed interaction with tamoxifen induced tumor regression in athy-mic mice with MCF-7 xenografts by down-regulating the expression of estrogen related gene products and signal transduction pathways. Nutr Cancer 58, 162-170. (Pubitemid 47328768)
14. Chen J, Power KA, Mann J, et al. (2007) Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen. Exp Biol Med (Maywood) 232, 1071-1080. (Pubitemid 47358190)
15. Chen J, Saggar JK, Corey P, et al. (2009) Flaxseed and pure secoisolariciresinol diglucoside, but not flaxseed hull, reduce human breast tumor growth (MCF-7) in athymic mice. J Nutr 139, 2031-2036.
16. Dabrosin C, Chen J, Wang L, et al. (2002) Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. Cancer Lett 185, 31-37. (Pubitemid 34876530)
17. Chen J, Stavro PM & Thompson LU (2002) Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr Cancer 43, 187-192. (Pubitemid 36134093)
18. Chen J, Wang L & Thompson LU (2006) Flaxseed and its components reduce metastasis after surgical excision of solid human breast tumor in nude mice. Cancer Lett 234, 168-175.
19. Wang L, Chen JM & Thompson LU (2005) The inhibitory effect of flaxseed on the growth and metastasis of estrogen receptor negative human breast cancer xenografts is attributed to both its lignan and oil components. Int J Cancer 116, 793-798. (Pubitemid 41099712)
20. Thompson LU, Chen J, Li T, et al. (2005) Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res 11, 3828-3835. (Pubitemid 40685603)
21. Boon HS, Olatunde F & Zick SM (2007) Trends in complementary/ alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 7, 4-10.
22. Oomah BD (2003) Processing of flaxseed fiber, oil, protein, and lignan. In Flaxseed in Human Nutrition, 2nd ed., pp. 363-403 [LU Thompson and SC Cunnane, editors]. Champaign: AOCS Press.
23. Oomah BD, Mazza G & Kenaschuk EO (1996) Dehulling characteristics of flaxseed. Lebensm Wiss Technol 29, 245-250. (Pubitemid 126168863)
24. Madhusudhan B, Wiesenborn D, Schwarz J, et al. (2000) Dry mechanical method for concentrating the lignan secoisolari-ciresinol diglucoside in flaxseed. Lebensm Wiss Technol 33, 268-275.
25. Saggar JK, Chen J, Corey P, et al. (2010) Dietary flaxseed lignan or oil combined with tamoxifen treatment affects MCF-7 tumor growth through estrogen receptor- and growth factor-signaling pathways. Mol Nutr Food Res 54, 415-425.
26. Canadian Council on Animal Care (1993) Guide to the Care and Use of Experimental Animals, vol. 1, 2nd ed. Ottawa: CCAC.
27. Reeves PG, Nielsen FH & Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123, 1939-1951. (Pubitemid 23342492)
28. Saggar JK, Chen J, Corey P, et al. (2010) The effect of secoi-solariciresinol diglucoside and flaxseed oil, alone and in combination, on MCF-7 tumor growth and signaling pathways. Nutr Cancer 62, 533-542.
29. Livak KJ & Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(2DDC(T)) method. Methods 25, 402-408. (Pubitemid 34164012)
30. Allred DC, Harvey JM, Berardo M, et al. (1998) Prognostic and predictive factors in breast cancer by immunohisto-chemical analysis. Mod Pathol 11, 155-168. (Pubitemid 28144151)
31. Furr BJ & Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25, 127-205. (Pubitemid 14015738)
32. Jordan VC (2001) The past, present, and future of selective estrogen receptor modulation. Ann N Y Acad Sci 949, 72-79. (Pubitemid 34059963)
33. MacGregor JI & Jordan VC (1998) Basic guide to the mechanisms of antiestrogen action. Pharmacol Rev 50, 151-196. (Pubitemid 28305723)
34. Ring A & Dowsett M (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643-658. (Pubitemid 40065543)
35. Duffy C & Cyr M (2003) Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health 12, 617-631. (Pubitemid 37266005)
36. Osborne CK, Bardou V, Hopp TA, et al. (2003) Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361. (Pubitemid 36395255)
37. Soto AM, Fernandez MF, Luizzi MF, et al. (1997) Developing a marker of exposure to xenoestrogen mixtures in human serum. Environ Health Perspect 105, Suppl. 3, 647-654. (Pubitemid 27247337)
38. Van Meeuwen JA, Ter Burg W, Piersma AH, et al. (2007) Mixture effects of estrogenic compounds on proliferation and pS2 expression of MCF-7 human breast cancer cells. Food Chem Toxicol 45, 2319-2330. (Pubitemid 47451586)
39. Ali S & Coombes RC (2002) Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev Cancer 2, 101-112. (Pubitemid 37328797)
40. Le Romancer M, Treilleux I, Leconte N, et al. (2008) Regulation of estrogen rapid signaling through arginine methylation by PRMT1. Mol Cell 31, 212-221. (Pubitemid 352005820)
41. Anzick SL, Kononen J, Walker RL, et al. (1997) AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277, 965-968. (Pubitemid 27366683)
42. Shou J, Massarweh S, Osborne CK, et al. (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/ neu cross-talk in ER/HER2-positive breast cancer. J Nat Cancer Inst 96, 926-935. (Pubitemid 38868139)
43. Nicholson RI, Hutcheson IR, Britton D, et al. (2005) Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies. J Steroid Biochem Mol Biol 93, 257-262. (Pubitemid 40602498)
44. Ghayad SE, Vendrell JA, Larbi SB, et al. (2009) Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. Int J Cancer 126, 545-562.
45. McClelland RA, Barrow D, Madden TA, et al. (2001) Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 142, 2776-2788. (Pubitemid 32575512)
46. Knowlden JM, Hutcheson IR, Jones HE, et al. (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodi-mers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044. (Pubitemid 36262870)
47. Butt AJ, McNeil CM, Musgrove EA, et al. (2005) Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12, Suppl. 1, S47-S59. (Pubitemid 41395413)
48. Mester J & Redeuilh G (2008) Proliferation of breast cancer cells: regulation, mediators, targets for therapy. Anticancer Agents Med Chem 8, 872-885.
49. Song RX, Chen Y, Zhang Z, et al. (2010) Estrogen utilization of IGF-1-R and EGF-R to signal in breast cancer cells. J Steroid Biochem Mol Biol 118, 219-230.
50. Santen RJ, Fan P, Zhang Z, et al. (2009) Estrogen signals via an extra-nuclear pathway involving IGF-1R and EGFR in tamoxifen-sensitive and -resistant breast cancer cells. Steroids 74, 586-594.
51. Gee JM, Robertson JF, Gutteridge E, et al. (2005) Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12, Suppl. 1, S99-S111. (Pubitemid 41395417)